Evaluation of Pharmaceutical Care in Depressed Outpatients

EVALUATION OF THE EFFECTIVENESS OF PHARMACEUTICAL CARE (DÁDER PROGRAM) IN DEPRESSED OUTPATIENTS TREATED WITH PSYCHOTROPIC

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01571973

Acronym

depression

Enrollment

Registered

2012-04-05

Start date

2010-03-31

Completion date

2012-05-31

Last updated

2012-04-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression

Keywords

pharmaceutical care, depression, compliance, pharmacist's intervention, Dáder

Brief summary

The study examines whether pharmacotherapeutic follow-up improves outcomes of treatment of depressed outpatients.

Interventions

PROCEDUREpharmacotherapeutic follow-up

health education adjustment of dose improve compliance replacement of medication

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

SUPPORTIVE_CARE

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* women between 18 and 65 years, with diagnostic hypothesis of depression at the beginning of treatment or change in treatment unless 2 months (dosage or substance)

Exclusion criteria

* record of dependence on psychoactive substances, diagnosed schizophrenia, * low education (illiterate) or cognitive impairment evident that compromise the completion of research instruments

Design outcomes

Primary

Measure	Time frame	Description
depression level	six months	evaluation depression level by Beck scale

Secondary

Measure	Time frame	Description
anxiety level	6 months	evaluation anxiety level by Beck scale.
compliance	6 months	evaluation antidepressive treatment compliance by Morisky scale

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026